Skip to main content
Show — Main navigation
Hide — Main navigation
Home
About
The Chair
Inquiry Team
Expert Groups
Inquiry Intermediaries
Core Participants
Legal Representatives
Financial Reports
Approach
Terms of reference
List of Issues
Statements of approach
Inquiry Principles
News
News
Newsletter Archive
Reports
The Inquiry Report
Additional Compensation report
First Interim Report
Second Interim Report
Compensation Framework Study
Evidence
Evidence
Hearings Archive
Compensation
Support
NHS Psychological Support
Confidential Psychological Support
Support Groups
Infected Blood Support Schemes
Treatment and aftercare
Medical Evidence
Expenses Guidance
Contact us
Search
Accessibility Tool
Zoom in
Zoom out
Reset
Contrast
Accessibility tool
Listen
Get in touch
Quick Exit
Subscribe to Search results
Search
Sort your search results
Relevance
Title
Changed
It was the view of the reference centre directors at the special meeting on 13 May 1983 that cryoprecipitate was not particularly easy to use as there was no guarantee of the amount of Factor 8 in each bag, and it was not a particularly useful therapeutic option for major surgery or major bleeds.
Published on:
27 September, 2024
Inquiry publishes timetable for further evidence from panels and expert groups
Published on:
31 August, 2022
The results of a survey between Sheffield and the Royal Free on chronic hepatitis showed that approximately one third of the patients studied had the appearance of chronic active (aggressive) hepatitis.
Published on:
27 September, 2024
A letter to The Lancet in 1982 reported that "we have previously shown that there is a high incidence of chronic liver disease among patients receiving blood product concentrates even in the absence of any symptoms."
Published on:
27 September, 2024
The annual return for 1976 showed the Sheffield Haemophilia Centre treating its patients with cryoprecipitate, NHS Factor 8 and commercial concentrates.
Published on:
27 September, 2024
It was noted in the Annual Returns for Sheffield Haemophilia Centre for 1977 'that "home treatment packs' from ARMOUR have been used most of the time for home therapy."
Published on:
27 September, 2024
In 1979 the Sheffield Haemophilia Centre's return recorded no cryoprecipitate use at all for people with Haemophilia A.
Published on:
27 September, 2024
Annual returns for Sheffield Haemophilia Centre in 1980 recorded that a small amount of cryoprecipitate was used, but the mainstay of treatment was commercial concentrate
Published on:
27 September, 2024
In 1980, in the Sheffield Haemophilia Centre, a small amount of cryoprecipitate was used, but the majority of treatment was commercial concentrate (4,690 units of cryoprecipitate; 141,775 units of NHS concentrate; 800,852 units of commercial concentrates (Factorate, Hemofil, Kryobulin)).
Published on:
27 September, 2024
Professor Eric Preston stated in his statement that cryoprecipitate was not a treatment option for severe haemophiliacs, and that this did not change over time.
Published on:
27 September, 2024
In Birmingham, Haemophilia care was split between the Children's Hospital and the Queen Elizabeth Hospital. They were jointly designated as a haemophilia centre in the 1970s
Published on:
27 September, 2024
In 1976 Dr Frank Hill succeeded Dr Jillian Mann as director at the Children's Hospital; Dr John Stuart was director at QEH until 1983 when he was succeeded by Dr Ian Franklin
Published on:
27 September, 2024
The West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs met regularly throughout the 1970s to discuss issues relating to supply
Published on:
27 September, 2024
In December 1975, the West Midlands Regional Health Authority recorded difficulties in producing sufficient plasma and it was agreed that commercial Factor 8 (Kryobulin) would need to be purchased at an annual cost to the region of £350,000.
Published on:
10 October, 2024
Demand for cryoprecipitate was going down and NHS concentrates were not being used at the rate that had been predicted
Published on:
27 September, 2024
In 1976 the Queen Elizabeth Hospital had used 500,000 units of commercial Factor 8 for home treatment, because all the NHS product having been used for treatment in hospital and for dental cases.
Published on:
27 September, 2024
During 1977 the Queen Elizabeth Hospital used significant amounts of commercial Factor 8 (almost double the amount from the previous year) as well as NHS Factor 8 (at a similar level to the previous year)
Published on:
27 September, 2024
At a Working Party meeting Dr Stuart stated that during 1976 Queen Elizabeth Hospital had used 500,000 units of commercial Factor 8 for home treatment, with all the NHS product having been used for treatment in hospital and for dental cases. He stated that his preference was to have all his Factor 8 from the same source, and that he was minded to discontinue cryoprecipitate as a home treatment and use NHS product instead.
Published on:
27 September, 2024
During 1977 Queen Elizabeth Hospital used significant amounts of commercial Factor 8 as well as NHS Factor 8
Published on:
27 September, 2024
Dr Stuart of Queen Elizabeth Hospital stated that only a third of Queen Elizabeth Hospital's Factor 8 product was received from the Lister, meaning the two-thirds shortfall had to be made up with commercial concentrates.
Published on:
27 September, 2024
Pagination
First page
First
Previous page
Previous
…
Page
2323
Page
2324
Page
2325
Page
2326
Current page
2327
Page
2328
Page
2329
Page
2330
Page
2331
…
Next page
Next
Last page
Last